INBRAIN Neuroelectronics
INBRAIN Neuroelectronics is a Barcelona-based, clinical-stage company developing graphene-based brain-computer interface implants to treat Parkinson's, epilepsy, stroke, and speech disorders. It partners with Merck KGaA, Mayo Clinic, and Microsoft, and holds FDA Breakthrough Device Designation for its Parkinson's program.
- Company typePrivate
- Founded2019
- HeadquartersBarcelona, Spain
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What INBRAIN Neuroelectronics does
INBRAIN Neuroelectronics is a Barcelona-based clinical-stage brain-computer interface (BCI) therapeutics company founded in 2019 that develops graphene-based cortical implants to treat neurological disorders. Its core technology replaces conventional metal electrodes with high-resolution, miniaturized graphene arrays capable of both recording neural activity and delivering adaptive stimulation. The company holds an FDA Breakthrough Device Designation for Parkinson's disease and has completed first-in-human clinical trials, with ongoing programs targeting epilepsy, stroke rehabilitation, and speech restoration.
The platform combines the proprietary graphene hardware with on-device and cloud-based AI algorithms that enable closed-loop, real-time adjustment of stimulation parameters based on decoded neural intent and disease-state biomarkers. Strategic partners — Merck KGaA for pharmaceutical-commercialization pathways, Mayo Clinic for US clinical translation, and Microsoft for Azure-integrated agentic AI and time-series LLM decoding — anchor the technology and clinical stack. The company has raised approximately $124M cumulatively, including a $50M Series B in October 2024, and is establishing a US presence via a Boston-area subsidiary.
Commercially, INBRAIN is pre-revenue: there are no marketed products. Future revenue mechanics are expected to follow the implantable Class III neuromodulation model — capital equipment plus per-implant consumables sold to neurosurgery centers and tertiary hospitals — supplemented by potential licensing or co-development income from strategic partners. Go-to-market is being prepared for the US first, leveraging the FDA Breakthrough Designation and Mayo Clinic clinical relationships, with Europe and other major neuromodulation markets likely to follow regulatory clearance.
INBRAIN Neuroelectronics firmographics
Firmographics- Name
- INBRAIN Neuroelectronics
- Legal name
- INBRAIN NEUROELECTRONICS SL
- Website
- https://inbrain-neuroelectronics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- INBRAIN Neuroelectronics is a Barcelona-based, clinical-stage company developing graphene-based brain-computer interface implants to treat Parkinson's, epilepsy, stroke, and speech disorders. It partners with Merck KGaA, Mayo Clinic, and Microsoft, and holds FDA Breakthrough Device Designation for its Parkinson's program.
- Ownership category
- akta.pro rank
INBRAIN Neuroelectronics industry classification
Industry- Product category
- Brain-Computer Interface Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where INBRAIN Neuroelectronics is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
INBRAIN Neuroelectronics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Graphene-based BCI Platform Commercialization: INBRAIN is developing and preparing to commercialize its graphene-based brain-computer interface platform for treating neurological disorders including Parkinson's disease, epilepsy, and stroke rehabilitation. The company has received FDA Breakthrough Device Designation for Parkinson's disease, supporting market entry pathway.
- INNERVIA Bioelectronics (Vagus Nerve Therapy): INBRAIN's subsidiary INNERVIA Bioelectronics develops and commercializes intelligent graphene systems to modulate vagus nerve signals in collaboration with Merck KGaA, targeting inflammatory, metabolic, and endocrine disorders.
- Merck KGaA Development Partnership: Strategic collaboration with Merck KGaA for cardiometabolic treatments development, with Merck signaling commercialization intent around INBRAIN's BCI-Tx platform.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
INBRAIN Neuroelectronics product offering
Product offeringCore offering
INBRAIN Neuroelectronics develops graphene-based brain-computer interface (BCI) therapeutics for neurological disorders. The end-to-end platform combines skin-like, high-resolution (up to 1024 contacts) bidirectional graphene cortical interfaces with an implantable compact neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. Targeted applications include Parkinson's disease, epilepsy, stroke rehabilitation, and speech disorders, with a vagus nerve interface line developed via the INNERVIA Bioelectronics subsidiary in partnership with Merck KGaA.
Product overview
INBRAIN Neuroelectronics is developing a three-vertical product platform based on graphene neural interface technology. The platform consists of a cortical interface (currently in first-in-human studies), an implantable system for Parkinson's disease (FDA Breakthrough Device Designation), and a vagus nerve interface for cardiometabolic applications (via INNERVIA Bioelectronics subsidiary). The core technology combines graphene-based high-resolution neural interfaces (up to 1024 contacts) with an implantable wireless neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. INNERVIA Bioelectronics, a subsidiary created with Merck KGaA, focuses on vagus nerve therapies for chronic inflammatory, metabolic, and endocrine disorders.
Differentiator
Problem solved
Functional benefit
Brands
- INNERVIA Bioelectronics: A subsidiary dedicated to the development and commercialization of intelligent graphene systems designed to modulate vagus nerve signals for treating chronic diseases, established in partnership with Merck KGaA
Products and services
- INBRAIN Graphene Neural Interface Platform (BCI-Tx) End-to-end neural platform combining skin-like, bidirectional, high-resolution (up to 1024 contacts) graphene brain-computer interfaces with an implantable compact neural processor (wireless rechargeable battery) and AI-powered analytics for real-time closed-loop decoding and modulation of brain activity. Designed for therapeutic applications in neurological disorders and as a research/surgical aid.
- BCI-Tx Chip (Rice-sized Bidirectional Graphene BCI) Bidirectional graphene brain-computer interface chip that combines graphene neural interfaces with integrated electronics to record and stimulate brain activity in closed loop, using AI-assisted algorithms for real-time parameter adjustment. Targeted for Parkinson's disease, epilepsy, stroke rehabilitation, and speech-decoding applications.
- Parkinson's Disease Implantable System Graphene-based implantable neuroelectronic system specifically developed for the treatment of Parkinson's Disease, having received FDA Breakthrough Device Designation. Targets the estimated $400 billion BCI market opportunity for therapeutic applications.
- INNERVIA Bioelectronics (Vagus Nerve Therapy Platform) Subsidiary platform developing intelligent graphene systems designed to modulate vagus nerve signals for treating chronic inflammatory, metabolic, and endocrine disorders. Co-developed with Merck KGaA's Innovation Center under a joint development and commercialization arrangement.
- Graphene Cortical Interface (Surgical / Intraoperative) First-in-human graphene-based cortical interface used during brain tumor resection surgeries to capture high-resolution neural signals and decode speech patterns, with demonstrated favorable safety profile and ability to differentiate healthy from cancerous tissue.
Quantifiable outcome
- No device-related adverse events observed in first-in-human trial with 8 patients over 90 days of monitoring
- +2 more outcomes
Companies that use INBRAIN Neuroelectronics
Customer profileSegments3 records
Ideal customer profiles2 records
INBRAIN Neuroelectronics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
INBRAIN Neuroelectronics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- MicrosoftcoreStrategic collaboration to utilize agentic AI powered by Microsoft's Azure AI infrastructure for advancing real-time precision neurology and next-generation brain-computer interface therapeutics. The partnership aims to enable INBRAIN's graphene-based neural platform to continuously learn and adapt to individual patient signals for closed-loop precision interventions.
- Mayo CliniccoreKnow-how collaboration agreement with Mayo Clinic to accelerate development and commercialization of graphene-based BCI therapeutics for patients with neurological disorders. Experts from both organizations conduct hands-on evaluation of INBRAIN's investigational BCI-Tx platform in IRB-approved clinical settings.
- ICN2 (Catalan Institute of Nanoscience and Nanotechnology)coreINBRAIN is a spin-off from ICN2 and ICREA. The company was founded based on graphene technology research developed at these institutions, and continues collaborative research relationships including the GphT-BCI project.
- University of Manchester / Northern Care Alliance NHS Foundation TrustcoreClinical trial sponsor and partner for first-in-human studies of graphene-based cortical interfaces during brain tumor resection surgeries conducted at Manchester Centre for Clinical Neurosciences and Salford Royal Hospital.
- KyndrylsupportingTechnology collaboration providing end-to-end digital infrastructure management including Microsoft Azure cloud services, on-premises infrastructure, data science platform development, and laboratory and production-grade environment design. Partnership renewed in 2026 to support Inbrain's transition from R&D to scalable, market-ready operations.
- Merck KGaAcoreJoint development agreement with Merck KGaA's Innovation Center to develop next-generation graphene bioelectronic vagus nerve therapies targeting severe chronic diseases. The collaboration created INNERVIA Bioelectronics as a subsidiary of INBRAIN focused on vagus nerve therapies for inflammatory, metabolic, and endocrine disorders. Merck has signaled commercialization intent around INBRAIN's BCI-Tx platform.
Scale indicators9 records
Recent moves10 records
Expansion highlights6 records
INBRAIN Neuroelectronics competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
INBRAIN Neuroelectronics social profiles
Digital presenceINBRAIN Neuroelectronics compliance and trust
Trust signalCompliance1 record
INBRAIN Neuroelectronics financial estimates
Financial estimateRevenue estimate
Valuation estimate
INBRAIN Neuroelectronics leadership team
Management profileNumber of profiles
Profiles18 records
INBRAIN Neuroelectronics subsidiaries and ownership
Company hierarchySubsidiaries1 record
INBRAIN Neuroelectronics funding detail
Funding detailFunding overview
Funding rounds12 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
INBRAIN Neuroelectronics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about INBRAIN Neuroelectronics
What does INBRAIN Neuroelectronics do?
INBRAIN Neuroelectronics develops graphene-based brain-computer interface (BCI) therapeutics for neurological disorders. The end-to-end platform combines skin-like, high-resolution (up to 1024 contacts) bidirectional graphene cortical interfaces with an implantable compact neural processor and AI-powered analytics for real-time closed-loop neural decoding and modulation. Targeted applications include Parkinson's disease, epilepsy, stroke rehabilitation, and speech disorders, with a vagus nerve interface line developed via the INNERVIA Bioelectronics subsidiary in partnership with Merck KGaA.
Is INBRAIN Neuroelectronics a public or private company?
INBRAIN Neuroelectronics is a private company. It is classified as venture growth investor backed and is currently operating.
When was INBRAIN Neuroelectronics founded?
INBRAIN Neuroelectronics was founded in 2019. It employs 51 to 100 people.
Where is INBRAIN Neuroelectronics based?
INBRAIN Neuroelectronics is headquartered in Barcelona, Spain, in the Europe region.
How does INBRAIN Neuroelectronics make money?
Three revenue lines are on record. Graphene-based BCI Platform Commercialization is the primary driver. The others are INNERVIA Bioelectronics (Vagus Nerve Therapy) and merck KGaA Development Partnership.
Does INBRAIN Neuroelectronics have an API?
No public API is recorded for INBRAIN Neuroelectronics.
What industry is INBRAIN Neuroelectronics in?
INBRAIN Neuroelectronics's product category is Brain-Computer Interface Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.